Recipe photos: Morgan Hunt Glaze and Jen Causey. EatingWell design.

A groundbreaking national poll conducted on behalf of the Diabetes Patient Advocacy Coalition (DPAC) reveals overwhelming ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Risk of suicidality wasn't higher for type 2 diabetes patients starting on GLP-1 receptor agonists than for those on two other popular classes of diabetes drugs, a U.K. cohort study found. In fully ...

Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with ...

In recent years, the pursuit of natural solutions to enhance metabolic health has gained prominence. Individuals are increasingly looking for ways to optimize their wellness without resorting to harsh ...

In response to the growing interest in glucagon-like peptide-1 (GLP-1) weight-loss medications and the cost challenges employers face to offer coverage, Liviniti, a national leader in PBM innovation, ...

We are excited to partner with the team at Tollo, who bring in-depth scientific and medical knowledge in both the areas of muscle loss and chronic viral infections”, said Jason Lang, Vice President of ...

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public ...

Dr. Kristen Kells, founder of Colorado Springs’ largest weight loss clinic, shared insights on GLP-1 drugs and explained why the Dr. Kells Method can offer better long-term ...